OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
June 15, 2016
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Contract service providers debate the pros and cons of consolidation, accelerated drug approvals, regulatory issues, and the impact of new therapies.
Planning ahead is key to enabling a continuous and secure supply chain that adapts to changes in market demand.
For successful drug delivery partnerships, it’s important to take a long-term view, focus on simple designs, and address potential payer concerns up front.
New drug approval policies promote industry growth and injectable contract manufacturing opportunities in China.
Biopharmaceutical manufacturers continue to put quality at the forefront of their relationships.
Adopting best practices and collaborating more closely with contract research organizations can help drugs get past Phase III.
Biopharmaceutical contractors continue to invest in development, facility upgrades, technological advancement, and mergers and acquisitions.